SEC Form 4 · accession 0001104659-26-073062
Apogee Therapeutics, Inc. · APGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jun 9, 2026
Accepted (ET)
Jun 11, 2026 · 8:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001974640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $85.00 | Jun 9, 2026 | A | 7,657 | A | — | Jun 9, 2036 | Common Stock | 7,657 | 7,657 | I |
Explanation of responses
- F1This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.
- F2Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.
Remarks
Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is a Managing Member of Fairmount.